The former case is the one presented by the carriers of the transmembrane 6 superfamily member 2 E167K gene variant (TM6SF2(EK/KK)) who have an increased risk of NAFLD and NASH, but unlike common ‘obese/metabolic’ NAFLD, these subjects lack hypertriglyceridemia and have a lower risk of cardiovascular disease. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatohepatitis.